ABBVCLS-484 is under clinical development by Calico Life Sciences and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Renal Cell Carcinoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ABBVCLS-484’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABBVCLS-484 is under development for the treatment of solid tumor, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and clear cell renal cell carcinoma. It is administered through oral route as capsule. It acts by targeting tyrosine-protein phosphatase non-receptor type 2 (PTPN2). It was also under development for the treatment of gastric cancer and adenocarcinoma of the gastroesophageal junction.
Calico Life Sciences overview
Calico Life Sciences (Calico) is a research and development company. It is operating its business as Calico Group LLC, is a life extension research and development company. It focusses on the discovery, development, and commercialization of therapies for the treatment of diseases of aging including neurodegeneration and cancer. It is focusing on both basic research and the translation of our discoveries into new interventions that can help people live healthier, and maybe longer, lives. It also engaged in research of advanced technologies to increase understanding of the biology that controls lifespan. Calico is headquartered in South San Francisco, California, the US.
For a complete picture of ABBVCLS-484’s drug-specific PTSR and LoA scores, buy the report here.